Skip to main content

Advertisement

Table 4 Activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of metastatic disease

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  All KRASwild-type KRASmutant
  L-L O/MM L-L O/MM L-L O/MM
Evaluable patients 25 32 12 18 13 14
Objective response (%; 95% CI) 21 (84; 69 to 99) 24 (80; 64 to 96) 12 (100) 15 (80; 59 to 100) 9 (67; 40 to 94) 9 (80; 54 to 100)
Partial response 18 22 10 13 8 9
Complete response 3 (12) 2 (6) 2 (17) 2 (11) 1 (8) -
Stable disease 2 3 - 2 2 3
Progressive disease 2 3 - 1 2 2
Liver metastasectomies, N (%) 17 (68) 1 (3) 10 (83) 1 (6) 7 (54) -
Pathologic complete responses 2 (12) - - - 2 -
Overall activitya, N (%) 20 (80) 3 (9) 12 (100) 3 (17) 8 (62) -
Median PFS, months 17 12 21 12 11 11
Range 3-69+ 1+44 8-69+ 4-44 3-60+ 1+37
Progression events 20 27 10 15 10 12
P value 0.034 0.044 0.354
Median OS, months 47 21 47 28 39 19
Range 8-69+ 1+66+ 18+69+ 1+66+ 8-60+ 1+59+
Deaths 12 23 4 13 8 10
P value 0.013 0.017 0.225
  1. aClinical complete response plus metastasectomies.
  2. L-L = liver limited; O/MM = other/multiple metastatic site; OS = overall survival; PFS = progression-free survival.